Clinical Trial Search

Primary: Change From Baseline for Average Blood Glucose (mg/dL) — 14.66; 33.88 mg/dL — p=0.0452

Primary: Number of Participants With Successful Vaginal Birth — 317 Participants

Primary: All-cause Mortality — 2269 Participants

Primary: Number of Participants in Each Category of Accrued Duration of Remission — 55; 32; 8; 8 Participants — p=<0.001

Primary: Language Skills at 4 Months After Baseline as Measured by the Pre-school Language Scale - 4th Edition — 84; 80.2 units on a scale

Primary: Proportion of Healthy Snacks Purchased — .403; .431; .429; .465 proportion of vends from healthy snacks

Primary: Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1) — 0.202; 0.477; 0.524; 0.573 Liters — p=<0.0001

Primary: Contraceptive Method Discontinuation — 300; 62; 142 Participants

Primary: Percentage of Participants Achieving Sustained Clinical Remission, Disease Activity Scale 28 - Erythrocyte Sedimentation Rate <26 (DAS28-ESR <2.6) at Week 20 and Week 24…

Primary: Overall Response Rate of Bortezomib and Rituximab (VR) in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (WM) — 30 Participants

Primary: Safety: Presence of Related/Not Related Local and/or Systemic Reactogenicity (Adverse Events) — 10; 17; 10; 29 Adverse Events

Primary: Evaluation of the Safety of RAD001 on Neurocognition in Patients With TSC Compared With Placebo in Patients With TSC. — 325; 147 Adverse Events

Primary: High End State Function — 56.52; 43.48; 56.52; 47.62 % people meeting high endstate status

Primary: Reaction Time — 512; 492; 524; 541 ms

Primary: Change From Baseline in Trough FEV1 at Treatment Visit Day 7 Compared to Placebo. — -0.0282; -0.0156; 0.0540; 0.0806 liters — p=0.9730